Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
0.9998
-0.0102 (-1.01%)
At close: Apr 2, 2026, 4:00 PM EDT
0.9306
-0.0692 (-6.92%)
After-hours: Apr 2, 2026, 5:18 PM EDT
Company Description
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company.
Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications.
In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
Tivic Health Systems, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Nov 11, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Michael Handley |
Contact Details
Address: 47685 Lakeview Blvd. Fremont, California 94538 United States | |
| Phone | 888 276 6888 |
| Website | tivichealth.com |
Stock Details
| Ticker Symbol | TIVC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001787740 |
| CUSIP Number | 888705308 |
| ISIN Number | US8887053085 |
| Employer ID | 81-4016391 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Michael Kevin Handley | Chief Executive Officer and Director |
| Lisa G. Wolf | Chief Financial Officer and Principal Financial and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 30, 2026 | 10-K | Annual Report |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 20, 2026 | 8-K | Current Report |
| Mar 13, 2026 | 8-K | Current Report |
| Mar 11, 2026 | 8-K | Current Report |
| Mar 4, 2026 | 8-K | Current Report |
| Feb 27, 2026 | SCHEDULE 13G | Filing |
| Feb 23, 2026 | 8-K/A | [Amend] Current report |
| Feb 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 9, 2026 | 8-K | Current Report |